ATXS
Price
$4.95
Change
+$0.17 (+3.56%)
Updated
Jun 3, 04:59 PM (EDT)
Capitalization
279.91M
69 days until earnings call
GLUE
Price
$4.64
Change
+$0.14 (+3.11%)
Updated
Jun 3, 04:59 PM (EDT)
Capitalization
285.41M
65 days until earnings call
Interact to see
Advertisement

ATXS vs GLUE

Header iconATXS vs GLUE Comparison
Open Charts ATXS vs GLUEBanner chart's image
Astria Therapeutics
Price$4.95
Change+$0.17 (+3.56%)
Volume$18.19K
Capitalization279.91M
Monte Rosa Therapeutics
Price$4.64
Change+$0.14 (+3.11%)
Volume$18.07K
Capitalization285.41M
ATXS vs GLUE Comparison Chart
Loading...
ATXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
GLUE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ATXS vs. GLUE commentary
Jun 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ATXS is a Buy and GLUE is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 04, 2025
Stock price -- (ATXS: $4.78 vs. GLUE: $4.50)
Brand notoriety: ATXS and GLUE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ATXS: 58% vs. GLUE: 104%
Market capitalization -- ATXS: $269.76M vs. GLUE: $285.41M
ATXS [@Biotechnology] is valued at $269.76M. GLUE’s [@Biotechnology] market capitalization is $285.41M. The market cap for tickers in the [@Biotechnology] industry ranges from $307.42B to $0. The average market capitalization across the [@Biotechnology] industry is $2.25B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ATXS’s FA Score shows that 0 FA rating(s) are green whileGLUE’s FA Score has 0 green FA rating(s).

  • ATXS’s FA Score: 0 green, 5 red.
  • GLUE’s FA Score: 0 green, 5 red.
According to our system of comparison, both ATXS and GLUE are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ATXS’s TA Score shows that 5 TA indicator(s) are bullish while GLUE’s TA Score has 5 bullish TA indicator(s).

  • ATXS’s TA Score: 5 bullish, 3 bearish.
  • GLUE’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, ATXS is a better buy in the short-term than GLUE.

Price Growth

ATXS (@Biotechnology) experienced а +21.94% price change this week, while GLUE (@Biotechnology) price change was +13.35% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +8.48%. For the same industry, the average monthly price growth was +5.47%, and the average quarterly price growth was +1.42%.

Reported Earning Dates

ATXS is expected to report earnings on Aug 11, 2025.

GLUE is expected to report earnings on Aug 07, 2025.

Industries' Descriptions

@Biotechnology (+8.48% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
GLUE($285M) and ATXS($280M) have the same market capitalization . GLUE YTD gains are higher at: -35.159 vs. ATXS (-46.532). GLUE has higher annual earnings (EBITDA): 6.14M vs. ATXS (-111.56M). ATXS (328M) and GLUE (326M) have equal amount of cash in the bank . ATXS has less debt than GLUE: ATXS (5.35M) vs GLUE (41.9M). GLUE has higher revenues than ATXS: GLUE (159M) vs ATXS (0).
ATXSGLUEATXS / GLUE
Capitalization280M285M98%
EBITDA-111.56M6.14M-1,816%
Gain YTD-46.532-35.159132%
P/E RatioN/A38.67-
Revenue0159M-
Total Cash328M326M101%
Total Debt5.35M41.9M13%
FUNDAMENTALS RATINGS
ATXS: Fundamental Ratings
ATXS
OUTLOOK RATING
1..100
20
VALUATION
overvalued / fair valued / undervalued
1..100
58
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
89
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ATXSGLUE
RSI
ODDS (%)
N/A
Bullish Trend 2 days ago
86%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
83%
Momentum
ODDS (%)
Bullish Trend 2 days ago
72%
Bullish Trend 2 days ago
89%
MACD
ODDS (%)
Bullish Trend 2 days ago
89%
Bullish Trend 2 days ago
89%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
87%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 6 days ago
80%
Bullish Trend 6 days ago
87%
Declines
ODDS (%)
Bearish Trend 26 days ago
90%
Bearish Trend 21 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
85%
Bearish Trend 2 days ago
88%
View a ticker or compare two or three
Interact to see
Advertisement
ATXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
GLUE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
BNIEX11.38N/A
N/A
UBS International Sustainable Equity A
SCATX61.57N/A
N/A
Virtus Zevenbergen Innovative Gr Stk I
HAGAX71.53N/A
N/A
Carillon Eagle Mid Cap Growth A
PSMKX51.96N/A
N/A
Victory Pioneer Select Mid Cap Growth R6
RPNIX10.44N/A
N/A
Riverpark/Next Century Gr Inst

ATXS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ATXS has been loosely correlated with CRNX. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if ATXS jumps, then CRNX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ATXS
1D Price
Change %
ATXS100%
+0.42%
CRNX - ATXS
53%
Loosely correlated
+4.49%
XENE - ATXS
53%
Loosely correlated
+4.23%
TRDA - ATXS
53%
Loosely correlated
+7.11%
KYMR - ATXS
53%
Loosely correlated
+45.51%
DNLI - ATXS
51%
Loosely correlated
+5.44%
More